https://orcid.org/0000-0002-1342-4692
Overview
My clinical and research interests are in the diagnosis and treatment of breast cancer. I am interested in clinical trial development and investigation of novel or new treatment options for patients with breast cancer. I am also interested in improving access to clinical trials to diverse patient populations.
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2022 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Overall survival by genomic profile in HER2-positive (HER2+) metastatic breast cancer (mBC): A large US clinico-genomic database study.
Conference Journal of Clinical Oncology · June 1, 2026 1045Background: Over the past few years, the landscape of treatment for HER2+ breast ... Full text CiteThe CROWN Study (CaRdiac Outcomes With Near-complete estrogen deprivation)
Conference CLINICAL CANCER RESEARCH · February 17, 2026 Link to item CiteFrequency, characterization, and clinical impact of unexpected cardiac and extracardiac imaging findings in premenopausal women on the CROWN study
Conference CLINICAL CANCER RESEARCH · February 17, 2026 Link to item CiteRecent Grants
A Phase 1/2, open label trial to investigate the safety, tolerability, and preliminary efficacy of EIS-12656 as single agent and in combination with a poly-ADP ribose polymerase (PARP) inhibitor or trastuzumab deruxtecan (T-DXd), an antibody drug
Clinical TrialPrincipal Investigator · Awarded by Eisbach Bio GmbH · 2026 - 2031A phase Ib/II multicenter, open-label, randomized study evaluating the safety, pharmacokinetics, and activity, of GDC-4198 along and in combination with giredestrant in comparison with abemaciclib in combination with giredestrant in participants with
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2026 - 2031A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy And Safety Of Inavolisib Plus A CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensit
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2026 - 2031View All Grants
Education
Boston University, School of Medicine ·
2016
M.D.